Sanofi (SNY) said Friday it stopped clinical testing and global regulatory applications for its amlitelimab medication for moderate-to-severe atopic dermatitis.
The company concluded the accumulated safety and effectiveness data does not support further progress for the skin condition, though a separate phase 2 study for the medication in celiac disease is expected to yield results in H2, the company said.
The decision will not alter the company's financial outlook for the full year, Sanofi said.
Shares of the company were down 1.5% in Friday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments